Sulisent

Canagliflozin (INN, trade name Invokana or Sulisent) is a drug of the gliflozin class or subtype 2 sodium-glucose transport (SGLT-2) inhibitors used for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson.

Medical use

Canagliflozin is an anti-diabetic drug used to improve glycemic control in people with type 2 diabetes. In extensive clinical trials, canagliflozin produced a consistent dose-dependent decrease in HbA1c levels of 0.77% to 1.16% when administered either as monotherapy, in combination with metformin, in combination with metformin and a sulfonylurea, in combination with metformin and pioglitazone, or in combination with insulin, from initial HbA1c levels of 7.8% to 8.1%. When added to metformin, canagliflozin 100 mg daily was shown to be non-inferior to both sitagliptin 100 mg daily and glimepiride in reducing HbA1c levels at one year, whilst canagliflozin 300 mg successfully demonstrated statistical superiority over both sitagliptin and glimiperide in decreasing HbA1c levels. Secondary efficacy endpoints of higher reductions in weight and blood pressure (versus sitagliptin and glimiperide) were also observed in studies. Canagliflozin produces beneficial effects on HDL cholesterol whilst increasing LDL cholesterol to produce no change in total cholesterol.

Name: Canagliflozin

CAS No.: 842133-18-0

Molecular formula: C24H25FO5S

Molecular weight: 444.52.

Systematic name:(1S)-1,5-Anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol.

ACD/LogP: 5.34±0.81

H bond acceptors: 5

H bond donors: 4

Freely Rotating Bonds: 9

Polar Surface Area: 118.39 Å2

Index of Refraction: 1.639

Molar Refractivity: 117.2±0.3 cm3

Molar Volume: 325.9±3.0 cm3

Polarizability: 46.5±0.5×10-24cm3

Surface Tension: 56.1±3.0 dyne/cm

Density: 1.4±0.1 g/cm3

Flash Point: 342.6±31.5 °C

Enthalpy of Vaporization: 99.7±3.0 kJ/mol

Boiling Point: 642.9±55.0 °C at 760 mmHg

Vapour Pressure: 0.0±2.0 mmHg at 25 °C

Canagliflozin is an experimental drug. It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90 % of the glucose reabsorption in the kidney.

Specifications:

Tests	Specifications	Results
Appearance	White or off-white powder	White powder
Identification:
A. IR(KBr)	The sample spectrum corresponds to that of the working standard	Confirm
B. HPLC	The retention time of the major peak in the chromatogram of the sample  corresponds to that exhibited by the working standard	Confirm
Single impurity	Not more than 0.1%	0.08%
Total impurities	Not more than 1.0%	0.5%
E.e %	More than 98.5%	99%
Assay (by HPLC)	Not less than 98.0% and not more than 102.0% w/w	99.1%
Conclusion	Comply with In-house standard.
Storage	Store protected from light and moisture

Packaging & Shipping:

25kg/drum or according to customer's requiement

Transit could be DHL,UPS,TNT,EMS,Fedex,and so on.

For mass orders, it will be delivered by air or sea.

Depending on your location, please allow 1-5 business days for your order to arrive.

For small order, please expect 3-7 days by UPS DHL EMS.

For mass order, please allow 5-8 days by Air, 15-30 days by Sea.

my contact infomation is:

Whatsapp: 008615032102186

Email: bettyapi1989@163.com 

Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body